secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001193125-24-141699
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve doubling authorized common stock to 300M shares
--------------------------------------------------------------------

- Charter amendment to increase authorized common stock from 150M to 300M shares approved with 42.7M for, 3.2M against.
- Class III directors Ashworth, Meyers, and Gilbert each elected with >24M votes for; broker non-votes of 17.6M.
- Ratification of Ernst & Young as auditor for FY2024 passed with 46.5M votes for.
- Advisory vote on executive compensation approved with 27.4M for, 1.9M against, 17.6M broker non-votes.
- All four stockholder proposals at May 15 Annual Meeting were approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/0001193125-24-141699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312524141699/d816353d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-141699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer